DailyIQ
|
Sector:HealthcareAll sectors
Last updated 2 minutes ago

MDT·Medtronic plc

$.
+. (+.%)
After Hours
High
$79.80
Open
$78.59
Market Cap
101.86B
52W High
$106.33
Low
$78.13
P. Close
$79.36
P/E
21.21
52W Low
$73.31
Fwd P/E
57.00
DailyIQ Est.
$100.34
Technical Score (1D)
41
SELL
News Sentiment
59
BULLISH
Analysts have recently reclassified Medtronic as undervalued, shifting the narrative from laggard to growth potential after fresh data. This change signals that the market may begin to price in stronger earnings momentum, which could lift the stock over the next 1–10 trading days. The company’s upcoming earnings report will be the key catalyst, as any upward revision to guidance or growth projections could confirm the new valuation premise. Investors should also keep an eye on Medtronic’s cost‑management initiatives, which have been highlighted as a driver for improved profitability. In addition, the firm’s low‑volatility profile and steady dividend yield provide a defensive cushion that could make it attractive to risk‑averse portfolios during any market turbulence. The stable demand for medical devices across economic cycles underpins this defensive appeal, suggesting that the stock may hold steady even if broader markets falter. The combination of a rebounding valuation narrative and a defensive dividend profile means that Medtronic could serve as both a growth and a defensive play in the near term. Watch for any changes in the company’s guidance during the earnings call, as well as any updates on product‑pipeline milestones that could further influence sentiment. Finally, monitor broader market volatility, as Medtronic’s low‑volatility nature may become more pronounced if a broader sell‑off occurs.
Earnings Summary
Medtronic plc is a global medical technology leader focused on developing and commercializing device‑based therapies across cardiovascular, neuroscience, medical surgical, and diabetes segments, operating in the highly regulated medical devices sector. In the most recent reporting cycle, the company posted Q3 2026 revenue of $9.017 billion and Q4 2026 revenue of $9.807 billion, reflecting a modest 0.6% increase from Q3 2025 to Q3 2026 and an 8.7% jump to Q4 2026; EPS rose from $1.36 in Q3 2026 to $1.55 in Q4 2026, beating the $1.5413 estimate and matching the $1.55 actual, while the Q3 2026 EPS fell short of the $1.68872 forecast. Compared with the prior two quarters (Q1 2025 and Q2 2025), Medtronic’s revenue growth accelerated from a 7.8% rise in Q1 2025 to a 5.1% increase in Q3 2025, then slowed to 0.6% in Q3 2026 before picking up again, and EPS has consistently beaten estimates in five of the last six quarters, with the sole miss occurring in Q3 2026. Historically, the company has maintained a steady YoY revenue growth trajectory, with Q4 2026 revenue up 9.9% YoY, and has repeatedly outperformed analyst expectations on EPS, underscoring disciplined cost management and robust core performance. Recent news highlights a market rally driven by renewed investor confidence, yet analysts caution that valuation remains high and that the rebound may be temporary; the firm’s FDA clearance for the Hugo RAS system in general and gynecologic surgery, coupled with ongoing cardiovascular device recalls, presents both growth opportunities and operational risks that could influence future guidance. Investors should watch for Medtronic’s upcoming earnings guidance on revenue growth and margin expectations, updates on recall resolution, and any further FDA clearance decisions, as these factors will likely shape the company’s valuation and short‑term market sentiment.

EPS

EstBeatMiss
$1.16$1.31$1.46$1.61$1.76Q1'25Q2'25Q3'25Q3'26Q4'26Q1'27
QtrEstActual+/−
Q1'27$1.39 - -
Q4'26$1.54$1.55+0.6%
Q3'26$1.69$1.36-19.5%
Q3'25$1.31$1.36+3.5%
Q2'25$1.23$1.26+2.5%
Q1'25$1.58$1.62+2.7%

Revenue

EstBeatMiss
$8.3B$8.8B$9.2B$9.6B$10.0BQ1'25Q2'25Q3'25Q3'26Q4'26Q1'27
QtrEstActual+/−
Q1'27$9.7B - -
Q4'26$9.7B$9.8B+0.8%
Q3'26$9.6B$9.0B-6.4%
Q3'25 - $9.0B -
Q2'25 - $8.5B -
Q1'25 - $8.9B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

MDT Stock Snapshot

MDT is currently trading at $79.09, giving Medtronic plc a market cap of 101.86B and a P/E ratio of 21.2. Today's range spans $78.13–$79.80, with shares opening at $78.59 and moving down $0.27 (0.3%) from the prior close. DailyIQ's technical score sits at 41/100 (HOLD) with a news sentiment reading of 59/100.

Over the past year MDT has traded between $73.31 and $106.33 - the current price is +7.9% off the 52-week low and -25.6% from the high. 38 analysts cover the stock with a Hold consensus and a mean 12-month target of $98.00 (range $78.00–$121.00), implying upside of +23.9%.

Neither bulls nor bears have the upper hand on Medtronic plc (MDT) right now. Score: 41/100 (HOLD). Sentiment: neutral (59/100). Price: $79.09 (near 52-week lows). (P/E: 21.2) At 101.86B in Healthcare market cap, the 52-week range of $73.31–$106.33 is the relevant frame - where the stock sits within that range, and whether volume confirms any directional move, matters more than the HOLD label alone.

Portfolio construction in Healthcare often uses large-cap names like MDT as tactical swing positions during neutral phases: cheap enough to overweight, liquid enough to exit quickly, and large enough to provide meaningful sector beta. The current 41/100 (HOLD) at $79.09 (near 52-week lows) and neutral sentiment (59/100) frame the position as a catalyst play within the $73.31–$106.33 annual range rather than a directional bet.